Atomoxetine – further delay in change of funded brand and open access
As at 20 May 2020.
PHARMAC advised all interested parties that there is a further one-month delay in the listing of a new funded brand of atomoxetine.
This applies to the listing of the Generic Partners’ brand of atomoxetine capsules (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg).
The on-going delays are due to manufacturing issues.
As a result, the listing date in Section B and Part II of Section H of the Pharmaceutical Schedule for all strengths will be moved to 1 July 2020, and the Special Authority and the Hospital Indication Restriction for atomoxetine will now be removed from 1 July 2020.
This also means the subsidy reduction in Section B for the currently funded Strattera brand will now occur from 1 September 2020. The Strattera brand will be delisted from Part II of Section H of the Pharmaceutical Schedule (hospital listing) on 1 September 2020 and from Section B (community listing) from 1 December 2020.
Dates of activities
For more information
For more details regarding the delay.
Who to contact
If you have any questions about this notification, you can email Pharmac directly at enquiry@pharmac.govt.nz or call them on their toll free number (9am to 5pm, Monday to Friday) on 0800 66 00 50.
PHARMAC advised all interested parties that there is a further one-month delay in the listing of a new funded brand of atomoxetine.
This applies to the listing of the Generic Partners’ brand of atomoxetine capsules (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg).
The on-going delays are due to manufacturing issues.
As a result, the listing date in Section B and Part II of Section H of the Pharmaceutical Schedule for all strengths will be moved to 1 July 2020, and the Special Authority and the Hospital Indication Restriction for atomoxetine will now be removed from 1 July 2020.
This also means the subsidy reduction in Section B for the currently funded Strattera brand will now occur from 1 September 2020. The Strattera brand will be delisted from Part II of Section H of the Pharmaceutical Schedule (hospital listing) on 1 September 2020 and from Section B (community listing) from 1 December 2020.
Dates of activities
- 1 July 2020 - Generic Partners atomoxetine listed in Schedule (Sections B and H)
- 1 July 2020 - Special Authority criteria removed (Sections B and H)
- 1 September 2020 - Hospital sole supply
- 1 September 2020 - Subsidy reduction for currently funded Strattera brand (reference pricing)
- 1 December 2020 - Community sole supply
- 1 December 2020 - Delisting of Strattera from Section B
- 1 December 2020 to 1 March 2021 - Brand switch fee applies for Generic Partners
For more information
For more details regarding the delay.
Who to contact
If you have any questions about this notification, you can email Pharmac directly at enquiry@pharmac.govt.nz or call them on their toll free number (9am to 5pm, Monday to Friday) on 0800 66 00 50.
